A phase II study of carboplatin and vinorelbine in patients with poor prognosis small cell lung cancer
HJ Mackay, M O'Brien, S Hill, SM Lees, N Thatcher… - Clinical Oncology, 2003 - Elsevier
Aim: The aim of this study was to evaluate the activity of the combination of carboplatin and
vinorelbine in patients with poor prognosis small cell lung cancer (SCLC). Patients with …
vinorelbine in patients with poor prognosis small cell lung cancer (SCLC). Patients with …
Carboplatin plus vinorelbine: A new active regimen in extensive small cell lung cancer. Results of a multicenter phase II study
C Gridelli, G Ianniello, L Brancaccio, F Perrone… - European Journal of …, 1997 - elibrary.ru
Purpose: Vinorelbine is a new vinca alkaloid that showed activity in small cell lung cancer
(SCLC) with about 30% of objective response (OR) in untreated patients (pts). To date there …
(SCLC) with about 30% of objective response (OR) in untreated patients (pts). To date there …
Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. Gruppo Oncologico …
C Gridelli, F Perrone, GP Ianniello… - Journal of clinical …, 1998 - ascopubs.org
PURPOSE To evaluate the activity and toxicity of the combination carboplatin plus
vinorelbine in extensive small-cell lung cancer (SCLC). PATIENTS AND METHODS A two …
vinorelbine in extensive small-cell lung cancer (SCLC). PATIENTS AND METHODS A two …
Carboplatin/etoposide/vincristine therapy in small cell lung cancer
U Gatzemeier, J von Pawel, R Laumen, DK Hossfeld… - Oncology, 1992 - karger.com
Carboplatin is one of the most active agents in untreated small cell lung cancer (SCLC; 14%
complete response, CR; and 61% CR+ partial response, PR). The combination …
complete response, CR; and 61% CR+ partial response, PR). The combination …
Phase II and III studies with carboplatin in small cell lung cancer.
U Gatzemeier, DK Hossfeld, R Neuhauss… - Seminars in …, 1992 - europepmc.org
Carboplatin is one of the most active agents in untreated small cell lung cancer (SCLC)(11%
complete response [CR], 59% CR plus partial response [PR]). Combination …
complete response [CR], 59% CR plus partial response [PR]). Combination …
Results of a phase II study of carboplatin plus gemcitabine in patients with untreated extensive small cell lung cancer
M Neubauer, R Heaven, J Olivares, A Otsuka… - Lung Cancer, 2004 - Elsevier
Purpose: To determine the response rate (RR) and survival produced by carboplatin+
gemcitabine therapy in patients with untreated extensive small cell lung cancer (ESCLC) …
gemcitabine therapy in patients with untreated extensive small cell lung cancer (ESCLC) …
Effective new low toxicity chemotherapy with carboplatin, vinblastine and methotrexate for small cell lung cancer: a randomised trial against doxorubicin …
AL Jones, J Holborn, S Ashley, IE Smith - European Journal of Cancer and …, 1991 - Elsevier
Carboplatin has been incorporated into a new low toxicity combination chemotherapy
regimen with methotrexate and vinblastine (CVM) against small cell lung cancer (SCLC). We …
regimen with methotrexate and vinblastine (CVM) against small cell lung cancer (SCLC). We …
Combination of vinorelbine plus gemcitabine in previously treated patients with small cell lung cancer: a multicentre phase II study
A Rapti, A Agelidou, I Stergiou, M Agelidou… - Lung cancer, 2005 - Elsevier
PURPOSE:: To evaluate the efficacy and toxicity of the gemcitabine plus vinorelbine
combination in pretreated patients with small cell lung cancer (SCLC). PATIENTS AND …
combination in pretreated patients with small cell lung cancer (SCLC). PATIENTS AND …
Randomized phase III study of carboplatin and paclitaxel versus vincristine, doxorubicin and cyclophosphamide chemotherapy in intermediate and poor prognosis …
S Baka, S Mullamitha, L Ashcroft, S Nagel… - Journal of Clinical …, 2006 - ascopubs.org
7059 Background: The combination of paclitaxel and carboplatin has been found to be
effective in lung cancer and well tolerated. Method: This is a phase III randomized trial of …
effective in lung cancer and well tolerated. Method: This is a phase III randomized trial of …
Combination chemotherapy with carboplatin, etoposide, and vincristine as first-line treatment in small-cell lung cancer.
U Gatzemeier, DK Hossfeld, R Neuhauss… - Journal of clinical …, 1992 - ascopubs.org
PURPOSE The antineoplastic activity of carboplatin and etoposide may be improved by the
addition of vincristine (CEV) because of its low myelosuppressive potential and its activity in …
addition of vincristine (CEV) because of its low myelosuppressive potential and its activity in …